I kliniske undersøgelser udviklede cirka halvdelen af infliximabbehandlede patienter, som var ANA negative ved baseline, en positiv ANA i løbet af undersøgelsen sammenlignet med cirka en femtedel af placebobehandlede patienter.
Approximately half of infliximab-treated patients in clinical studies who were ANA negative at baseline developed a positive ANA during the study compared with approximately one-fifth of placebo-treated patients.